Glenmark Pharmaceuticals operates a global formulations business across India, North America, Europe and emerging markets, with India as the anchor: in Q1 FY27 India formulation revenue was INR14,321 million, up 15.5% year on year, ranked 13th in the Indian market with 2.37% share and top positions in dermatology (2nd) and respiratory (3rd). The company makes money by selling branded and generic drugs, increasingly in differentiated formats: a US marketing portfolio of 225 products with 53 ANDAs pending, and a branded European portfolio that is expected to grow from about 30% of Europe revenue to 60% over five years. The blended EBITDA margin has been around 23% in recent quarters, with FY27 guided at 21-22% due to logistics and input cost pressure, which is above typical formulation averages and reflects a mix shifting toward respiratory, oncology and specialty products.
The economics persist because of qualification cycles, exclusivity and switching costs. The US Fluticasone Propionate 44mcg generic to Flovent HFA received CGT designation and 180-day exclusivity as the first approved applicant, creating a protected window and high pharmacy-and-patient stickiness. The Monroe injectables facility received EIR with VAI status and restarted commercial production, targeting 3+ filings per year in complex injectables, which take years to replicate. RYALTRIS is the leading nasal spray for allergic rhinitis in most launched markets, commercialized in 57 markets with MA applications in more than 90, and global secondary sales grew over 40% year on year. IGI's multi-specific antibody platform was validated by the AbbVie deal for ISB-2001 with $700 million upfront and total potential value up to $1.925 billion plus royalties, a barrier that few generics companies possess. This is not a commodity generics business; it is a converter with regulatory exclusivities and proprietary biologic platforms.
The inflection is already underway. In FY27, management guides consolidated revenue to approximately INR17,000-18,000 crores. Fluticasone 44mcg launched and should see full-quarter benefit in Q2 FY27; 2-3 more respiratory approvals are expected in H2 FY27; Aumolertinib first commercial launch is anticipated in H2 FY27; Trastuzumab Rezetecan first wave of MA applications begins in Q2 FY27; Envafolimab first commercial launch is expected in FY28; and RYALTRIS is scheduled for Brazil in H2 FY27. By 18-24 months out, the US respiratory portfolio should be generating recurring revenue from multiple approved products, Monroe injectables will contribute beginning FY28, and the Europe branded mix will be closer to 50-60%. India business is targeting over INR4,800 crores in FY27 with long-term 12-15% growth; oncology launches TEVIMBRA and BRUKINSA did over INR100 crores in their first 12 months. RYALTRIS has a stated path from roughly $100 million in FY26 toward $200-250 million in 3-5 years, and EBITDA margin should move from FY27's 21-22% toward 23-25% as fixed costs are absorbed.
Management walk-talk has been mixed but mostly delivered. In May 2025 they guided FY26 revenue growth of 10-12% and EBITDA margin of 19-20%; nine-month revenue growth came in at 31% and Q3 FY26 EBITDA printed at 23%, beating the top end. They achieved zero gross debt by end FY26 and brought Monroe back to FDA-approvable status after receiving EIR in Q3 FY26. But earlier promises slipped: generic Flovent 44mcg approval moved from end-Q2 to a later quarter, and the 5-6 US filings planned for FY26 were only 2 in Q3 with 3 more expected in Q4. The August 2026 call reaffirmed FY27 operating margin guidance of 21-22%, lower than the earlier 23% immediate language, citing two more quarters of logistics and input cost pressure. Capital allocation is disciplined: capex around INR700-900 crores annually, R&D spend at 7-8% of revenue, IGI funded at $70-75 million per year, and no gross debt. Management commitments for H2 FY27 include 2-3 respiratory approvals, Aumolertinib launch, and Trastuzumab Rezetecan MA filings.
The quantified earnings path is FY27 revenue of INR17,000-18,000 crores at 21-22% EBITDA margin, zero gross debt, and net working capital of 115 days. For that to hold, the US regulatory pipeline must convert: Fluticasone 110mcg, nasal spray and ipratropium approvals in H2 FY27, plus Monroe commercial production with 3+ complex injectable filings per year. The single most important watchpoint is US approval timing; failure to secure respiratory approvals on schedule would hit both revenue and margin because fixed costs at Monroe and the US infrastructure are already built. The tension in the data is an operating margin guided down to 21-22% despite gross margin being maintained; that is a cost and logistics issue, not structural erosion, and management expects mix improvement from new launches to offset it over the next 2-3 quarters. If approvals convert and RYALTRIS scales, the business 18-24 months out will have a diversified specialty portfolio, a branded Europe mix near 60%, an India business growing at 12-15%, and EBITDA margins trending toward 25%.
companyname: Glenmark Pharmaceuticals Limited ticker: GLENMARK sector: Pharmaceuticals Glenmark Pharmaceuticals is a Mumbai-headquartered global pharma company present in more than 80 countries, with FY26 consolidated revenue of INR 1,69,825 Mn (roughly USD 2 billion), up 27.5% year over year (FY26 integrated annual report). The business is structured as four regional operations - India, North America, Europe, and Emerging Markets - plus a clinical-stage biologics arm, Ichnos Glenmark Innovatio...
Read the full report →capex, margin expansion, regulatory approval, debt reduction
FY27 Revenue ~₹17,000-18,000 crores (approx. 15% growth)
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Glenmark Pharmaceuticals Limited and 4,900+ companies.
5-day free pass. No card required.